GLP-1 medications are both highly effective and wildly popular, prescribed for diabetes, weight loss and a growing list of connected conditions. New data from the Centers for Disease Control and Prevention suggests that, in the real world, millions of Americans are using them in ways regulators never approved.
In a report published this week in the CDC's Morbidity and Mortality Weekly Report, researchers analyzed survey data collected between July and August 2025 through the agency's Rapid Surveys System. Based on responses from 8,118 adults — 976 of whom reported GLP-1 use — the researchers estimate that about one in 10 US adults (9.8%), or roughly 27 million people, took a GLP-1 medication in the past year. Use scaled with body mass index and chronic conditions: prevalence was 4.8% among adults aged 18–39 but 13.7% among those 40–64; 47.4% of people who had ever had diabetes reported use.
The more striking findings concerned how people take the drugs. Overall, 44% of GLP-1 users said they had modified their use from the way it was prescribed — most commonly by skipping doses (28%), but also by taking less than prescribed or delaying refills. Modification was far more common among younger users: 54% of adults aged 18–39, versus 30% of those 65 and older, who were also much more likely to delay filling prescriptions (37% versus 6%).
Compounded GLP-1s — made by compounding pharmacies to mimic drugs like Wegovy or Ozempic, and never reviewed by the FDA for safety, effectiveness or quality — were used by 22.6% of GLP-1 users, with an additional 8.8% unsure whether their product was compounded. Among people using compounded versions, 62% said they were not taking them as prescribed, compared with 36% of those on brand-name drugs.
Cost and access were the dominant drivers. Of users who modified their medication use, 38% cited cost and 36% cited availability; 58% of adults aged 18–39 pointed to cost, against just 20% of those 65 and older. About 12% of users said they had reduced or stopped taking their medication because of side effects.
Compounded products carry elevated risk: the CDC notes that analyses of FDA adverse event reports show disproportionately higher rates of preparation errors, contamination and manufacturing problems. A recent assessment of websites selling compounded GLP-1s found nearly 40% stated or implied the drugs were FDA-approved, and roughly 80% used brand names in advertising — a violation of FDA standards.
The authors call for more research into these real-world practices, saying data on the safety and effectiveness of dose and frequency adjustments 'could help guide the development and implementation of clinical guidelines.'



